Pharmaceutical companies

How Pfizer’s Vaccine Announcement Demonstrates the Political Power of Firms

By timing the disclosure of the results of its vaccine trial, Pfizer could have influenced the 2020 presidential election. This is worrisome...

Regulators Should Keep a Close Eye on the Little Guys in the Race for a Covid-19 Vaccine

As the race to find a Covid-19 vaccine or treatment rages on, many have raised concerns over trustworthiness of clinical research and...

Paid to Show the Drug Works: Why “Blind” Clinical Trials for New Drugs are Far Less Blind Than They Should Be

New research shows that physicians in industry-sponsored trials are more captured by pharmaceutical companies than physicians in unsponsored ones.

The Amazon of Health Care: How CVS Is Evolving From a Drug Store Chain into a Tech Platform

CVS is built on a dominant chain of drug stores, but it is now trying to turn itself into a "uniquely powerful platform" for...

The Rise of the Opioids: How Purdue Invented New Markets for OxyContin

Purdue's strategy was to market its opioids directly to patients via brochures, videos, advertisements, and the internet. It also provided information to doctors and...

Purdue Circumvented the Regulator to Promote OxyContin, Hiding Its Real Risk of Addiction

In 2001, the Food and Drug Administration required Purdue to change OxyContin’s patient package inserts to make addiction risks more evident. The company altered...

“Short Sellers Don't Exist to Fix the Problems. They Exist to Shed Light on the Problems”

In an interview with ProMarket, Fahmi Quadir, the short seller whose bet against Valeant in 2015 helped expose the company's misdeeds, talks about short...

Editors’ Briefing: On Our Radar This Week (March 3-March 10)

This week in political economy.     ProPublica has created a searchable database of 2,475 political appointees by the Trump administration, the result of “a year...

The Secret Driver of US Health Care Costs: Politicians Wanting to Get Reelected

A pioneering new study provides a first-of-its-kind look into the outsized effect that lobbying and political maneuverings have on health care spending. Americans spend significantly more...

Perverse Market Incentives Encourage High Prescription Drug Prices

Pharmacy benefit managers (PBMs) are the under-discussed market participants who manage prescription drug insurance for the vast majority of Americans. PBMs claim to be a lone...

LATEST NEWS

George Stigler on Henry Simons, “Crown Prince” of the Chicago School

To mark 75 years since the passing of Henry Simons, professor of Economics and Law at the University of Chicago, ProMarket is...

Electoral College Reform: New Problems or Real Solutions?

Each electoral system creates specific incentives to (mis)allocate government resources. Would putting the National Popular Vote (NPV) in lieu of the Electoral...

When Do Users Benefit From Platform Mergers?

A new paper shows that platform mergers can harness network effects at the cost of reducing the platform differentiation that users value. 

Harold Demsetz and Israel Kirzner Understood That Competition Regulates Markets

Economists Harold Demsetz and Israel Kirzner challenged the prevailing orthodoxy in microeconomic analysis and public policy beginning with their respective work in...

The Covid-19 Pandemic Should Not Delay Actions to Prevent Anticompetitive Consolidation in US Health Care Markets

Harvard Business School professor Leemore Dafny lays out potential reforms to assist agencies in halting anticompetitive acquisitions and practices, and to preserve...